Back to search results

Haploidentical Stem Cell Transplant with Bortezomib for Blood Cancers

This study is looking at a type of stem cell transplant called a haploidentical transplant for people with blood cancers (hematological malignancies) who don't have a fully matched donor. It's testing if adding the drug Bortezomib to the usual treatment (post-transplant cyclophosphamide) can help prevent graft-versus-host disease (GVHD), a common complication where the donor cells attack your body. The study aims to see how well the new stem cells engraft (start growing) in your body within 30 days after the transplant. You might be able to join if you are 18-65 years old, have a blood cancer, and have a partially matched family donor. The study is currently unclear on its recruitment status and plans to enroll 15 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 15 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured within 30 days post-transplant, focusing on engraftment rate.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03850366

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Henry Ford Health System
~15 participants
Updated 2026-02-24 on ClinicalTrials.gov
What's tested:Bortezomib

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
engraftment rate
Measured over within 30 days post transplant

Conditions

Hematological Malignancy

Explore related trials

Hematologic Neoplasm

Where it's being run

1 sites across 1 states
Michigan1

Who to contact

shatha farhan
[email protected]
313 713 3910
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-65 years old patient lacking a matched related donor or unrelated donor but have a related haploidentical donor (\</= 7/8 allele match at the A, B, C, DR loci with a minimum match of 5/10 is required) is identified
Candidate for stem cell transplant in a malignant hematological condition
Karnofsky Performance Scale 0-1
Available donor able to undergo a Peripheral blood stem cells collection
Bilirubin \</= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \</= 200 IU/ml for adults.
Serum creatinine clearance \>/=60 ml/min (calculated with Cockroft-Gault formula)
Diffusing capacity for carbon monoxide (DLCO) \>/= 45% predicted corrected for hemoglobin.
Left ventricle ejection fraction \> 40%.
Patient or patient's legal representative, parent(s) or guardian should provide written informed consent.

Exclusion

Adult who has a suitable related or unrelated donor or cord units available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation
HIV positive; active hepatitis B or C
Patients with active uncontrolled infections.
Liver cirrhosis
Uncontrolled central nervous system involvement by tumor cells
Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
Inability to comply with medical therapy or follow-up

What this trial measures

  • engraftment ratewithin 30 days post transplant

    rate of neutrophil and platelet engraftment post stem cell transplant